Abstract PR01: Assessment of PARPi and cisplatin resistance in BRCA1 exon 11 mutant patient -derived xenografts

Introduction: The BRCA1 protein contributes to homologous recombination (HR) repair of DNA breaks. BRCA1 mutations often result in dysfunction or absence of BRCA1 proteins. Consequently, BRCA1 mutations induce PARP inhibitor (PARPi) and cisplatin sensitivity. BRCA1 exon 11 is the largest exon and harbors a plethora of germline mutations. BRCA1 exon 11 is subject to alternative splicing and can generate the BRCA1-Δ11q isoform. This isoform is a...